Cell analysis instruments provider Cytek BioSciences prices upsized IPO at $17 midpoint

Cytek BioSciences, which provides cell analysis instruments for life science applications, raised $285 million by offering 16.7 million shares (30% secondary) at $17, within the range of $16 to $18. The offering contained 2.2 million more shares than anticipated.

Cytek Biosciences' core products are the Aurora and Northern Lights systems, which are full spectrum flow cytometers that deliver high-resolution cell analysis by using the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells, also known as full spectrum profiling. As of March 31, 2021, the company has placed over 750 instruments to over 620 companies around the world, including pharmaceutical companies, over 125 biopharma companies, academic research centers, and clinical research organizations.

Cytek BioSciences plans to list on the Nasdaq under the symbol CTKB. Morgan Stanley, Goldman Sachs, Piper Sandler, and Cowen acted as joint bookrunners on the deal.

The article Cell analysis instruments provider Cytek BioSciences prices upsized IPO at $17 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.